Asset Details
Do you wish to reserve the book?
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Do you wish to request the book?
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
2018
Overview
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.
Publisher
eLife Sciences Publications Ltd,eLife Sciences Publications, Ltd
Subject
Biochemistry and Chemical Biology
/ Biology
/ BRD9
/ Cancer
/ CRISPR
/ Disease
/ Gene Expression Regulation, Neoplastic
/ Genomes
/ Genomics
/ Humans
/ Oncology
/ Proteins
/ Sarcoma, Synovial - genetics
/ Sarcoma, Synovial - pathology
/ SS18-SSX
/ SWI/SNF
/ Transcription Factors - chemistry
/ Transcription Factors - metabolism
/ Tumors
